109 related articles for article (PubMed ID: 30032478)
1. The changing cost of breast cancer care: lessons from a centralised modern cancer centre.
Joyce DP; O'Neill C; Heneghan HM; Curran C; Barry K; Sweeney K; Malone C; McLaughlin R; Kerin MJ
Ir J Med Sci; 2019 May; 188(2):409-414. PubMed ID: 30032478
[TBL] [Abstract][Full Text] [Related]
2. An economic evaluation of the optimal workload in treating surgical patients in a breast unit.
Pagano E; Ponti A; Gelormino E; Merletti F; Mano MP
Eur J Cancer; 2003 Apr; 39(6):748-54. PubMed ID: 12651199
[TBL] [Abstract][Full Text] [Related]
3. Metastatic breast cancer: we do need primary cost data.
Bonastre J; Jan P; Barthe Y; Koscielny S
Breast; 2012 Jun; 21(3):384-8. PubMed ID: 22520336
[TBL] [Abstract][Full Text] [Related]
4. Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran.
Ansaripour A; Zendehdel K; Tadayon N; Sadeghi F; Uyl-de Groot CA; Redekop WK
PLoS One; 2018; 13(10):e0205079. PubMed ID: 30273393
[TBL] [Abstract][Full Text] [Related]
5. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region].
Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM
Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006
[TBL] [Abstract][Full Text] [Related]
6. [Macro-economic calculation of spending versus micro-economic follow-up of costs of breast cancer].
Borella L; Paraponaris A
Rev Epidemiol Sante Publique; 2002 Dec; 50(6):581-92. PubMed ID: 12515928
[TBL] [Abstract][Full Text] [Related]
7. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
Nerich V; Chelly J; Montcuquet P; Chaigneau L; Villanueva C; Fiteni F; Meneveau N; Perrin S; Voidey A; Monnot T; Pivot X; Limat S
J Oncol Pharm Pract; 2014 Oct; 20(5):362-8. PubMed ID: 24158979
[TBL] [Abstract][Full Text] [Related]
8. [Cost effectiveness evaluation of breast cancer therapy. Comparative analysis 1975-1985 in a cancer prevention center].
Lapeyre-Mestre M; Daly-Schveitzer N; Boussin G; Delande G
Rev Epidemiol Sante Publique; 1993; 41(5):397-406. PubMed ID: 8284480
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a surveillance programme for women with a family history of breast cancer.
Reis MM; Tavakoli M; Dewar J; Goudie D; Cook A; McLeish L; Young D; Kenyon J; Steel M
J Med Genet; 2009 May; 46(5):319-23. PubMed ID: 19279022
[TBL] [Abstract][Full Text] [Related]
10. A cost analysis of a community-based support centre for cancer patients and their families in Ireland: the EVeCANs study.
Murphy A; Chu RW; Drummond FJ
Support Care Cancer; 2021 Feb; 29(2):619-625. PubMed ID: 32415384
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
12. Interpreting the economic literature in oncology.
Grusenmeyer PA; Wong YN
J Clin Oncol; 2007 Jan; 25(2):196-202. PubMed ID: 17210940
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
14. Economic analysis of cancer treatment costs: another tool for oncology managers.
Chirikos TN; Ruckdeschel JC; Krischer JP
J Oncol Manag; 2001; 10(3):11-7. PubMed ID: 11548179
[TBL] [Abstract][Full Text] [Related]
15. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of individual psychosocial support interventions for breast cancer patients in a randomized controlled study.
Arving C; Brandberg Y; Feldman I; Johansson B; Glimelius B
Psychooncology; 2014 Mar; 23(3):251-8. PubMed ID: 24115469
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
18. [Cost of treatment and follow up of breast cancer: a retrospective assessment in a comprehensive cancer centre].
Lilliu H; Stevens D; Brun C; Morel J; Pen CL; Bonastre J; Bachelot F; Davesne C; Gentile A; Hirlimann E; Sabourin JC; Berlie J; Rouëssé J
Bull Cancer; 2002 Jun; 89(6):635-42. PubMed ID: 12135864
[TBL] [Abstract][Full Text] [Related]
19. Cost of breast cancer based on real-world data: a cancer registry study in Italy.
Capri S; Russo A
BMC Health Serv Res; 2017 Jan; 17(1):84. PubMed ID: 28122558
[TBL] [Abstract][Full Text] [Related]
20. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
Montero AJ; Avancha K; Glück S; Lopes G
Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
